Phase I/II Trial of Iadademstat with Atezolizumab or Durvalumab in Extensive Stage Small Cell Lung Cancer
The trial evaluates the safety and efficacy of iadademstat combined with atezolizumab or durvalumab in extensive stage small cell lung cancer.
Phase I
Oncology / Small Cell Lung Cancer
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of iadademstat in combination with atezolizumab or durvalumab could significantly alter treatment paradigms for extensive stage small cell lung cancer. Successful outcomes may enhance competitive positioning and broaden therapeutic options in a challenging oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for efficacy and safety data, as well as any subsequent regulatory filings.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.